Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Other illness

• (1) Patients with severe internal diseases and severe impairment of liver and kidney function;
  • (2) Disease progression, extrauterine metastasis (cervical invasion or distant metastasis such as pelvic cavity) during treatment;
  • (3) People with therapeutic drug allergies and contraindications;
  • (4) Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; Patients with breast cancer or other hormone-dependent tumors that cannot use progesterone;
  • (5) Patients with deep vein thrombosis, stroke and myocardial infarction during treatment;
  • (6) Alcoholics (\> 20g/ day);
  • (7) Smokers (\> 15 cigarettes/day)

• The pathological types are consistent with:
  • Atypical endometrial hyperplasia;
  • Patients with highly differentiated endometrioid adenocarcinoma, stage IA, and pelvic and abdominal MRI before treatment excluded deep muscle infiltration, cervical involvement, and extrauterine metastasis;
  • There is a strong need to preserve reproductive function; Age ≤45 years old;
  • Progesterone resistant patients predicted by the progesterone sensitivity prediction model (NCT05647109) established by our team in the previous study of endometrial cancer were prospectively randomized; The predicted progesterone sensitive patients were prospectively observed;
  • Informed consent and signed informed consent;
  • have follow-up conditions and are willing to continue to follow the visitors in the hospital;
  • Patients with normal/abnormal blood lipids who have not taken any lipid-lowering drugs;
  • A. Newly treated patients: did not use any nursery therapy drugs (progesterone, GNRH-a); B. 1 course of treatment (12 weeks) the lesions persisted; C. Partial remission for 2 courses of treatment (24 weeks);